History of interstitial lung disease.
History of interstitial lung disease
Has a history of interstitial lung disease.
History of interstitial lung disease
Patients with history of interstitial lung disease.
Patient has a known history of chronic interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Has a history of interstitial lung disease related to prior EGFR inhibitor therapy.
Has a history of interstitial lung disease
History of interstitial lung disease.
Has a history of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Has interstitial lung disease that has required oral or intravenous glucocorticoids to assist with management.
Subjects with a history of interstitial lung disease
Has a history of interstitial lung disease
Subjects with a history of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
History of interstitial lung disease
Clinically significant interstitial lung disease
Patient has interstitial lung disease
Symptomatic interstitial lung disease
Persistent proteinuria ? grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Has a known history of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease
Subjects with a history of interstitial lung disease.
Has a history of interstitial lung disease
Has a history of interstitial lung disease.
History or active interstitial lung disease
Known interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Patient has a known history of chronic interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease
Interstitial lung disease
Clinically significant interstitial pulmonary disease or known diagnosis of interstitial lung disease (ILD)
Patients have history of diagnosed interstitial lung disease
Patients with interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
Subjects with a history of symptomatic interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Has a history of interstitial lung disease.
Interstitial lung disease
Active or prior documented interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Patients with known and confirmed diagnosis of interstitial lung disease (IDL)
Patients with clinically significant interstitial lung disease or history of cardiac disease
Patients with active interstitial lung disease
Patients must not have any known clinically active interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease
History of interstitial lung disease
History of interstitial lung disease
Has a history of interstitial lung disease.
History of symptomatic or p previously established interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
History of or active interstitial lung disease
Subjects with a history of interstitial lung disease
History of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Subjects with a history of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of or current interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Subjects with clinically significant interstitial lung disease, or obstructive disease without sufficient reserve
History of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of screening
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of screening.
History or concurrent condition of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Has a known history of interstitial lung disease
Has a history of interstitial lung disease
Known interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of study registration.
History of interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Has a history of interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
Patients with a history of interstitial
Non-malignant interstitial lung disease;
Radiographically evident interstitial lung disease , concurrent infection, or a history of any of these conditions
Interstitial lung disease with ongoing signs and symptoms at the time of screening
Interstitial lung disease with ongoing signs and symptoms at the time of registration
History of interstitial lung disease
Known or suspected history of interstitial lung disease.
History of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Any serious intercurrent or psychiatric illness that could, in the investigatorâ€™s opinion, potentially interfere with the completion of treatment according to this protocol including but not limited to: \r\n* Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL or 7.2 mmol/L)\r\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease\r\n* Active infections \r\n* Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease; malabsorption syndromes\r\n* Patients with enteric stomata or significant bowel resection\r\n* Prior history of corneal ulceration\r\n* Patients with any evidence of severe or uncontrolled systemic liver disease including those with known hepatitis B and hepatitis C (excluding treated hepatitis C that has been cured)\r\n* Active bleeding diatheses
Active interstitial lung disease; asthma requiring more than as needed bronchodilators for management; or other autoimmune lung disease
Has interstitial lung disease
Has history of interstitial lung disease.
Has active, or a history of, interstitial lung disease.
Known interstitial lung disease.
History of interstitial lung disease (Parts D and E only).
